Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Zhejiang Orient Gene Biotech Co's Revenue for the
three
months ended in Jun. 2026 was ¥208 Mil. Zhejiang Orient Gene Biotech Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was ¥172 Mil.
Hence, Zhejiang Orient Gene Biotech Co's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.21.
Zhejiang Orient Gene Biotech Co (SHSE:688298) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Zhejiang Orient Gene Biotech Co Receivables Turnover Related Terms
Zhejiang Orient Gene Biotech Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Orient Gene Biotech Co Receivables Turnover Chart
SHSE:688298 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Zhejiang Orient Gene Biotech Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Orient Gene Biotech Co Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zhejiang Orient Gene Biotech Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Zhejiang Orient Gene Biotech Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Orient Gene Biotech Co (SHSE:688298) has a Receivables Turnover of 1.21 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. According to the industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #454 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 56%.
Is Zhejiang Orient Gene Biotech Co's Receivables Turnover too high?
Zhejiang Orient Gene Biotech Co's current Receivables Turnover is 1.21. The Medical Devices & Instruments industry median Receivables Turnover is 5.58. Zhejiang Orient Gene Biotech Co's value of 1.21 is 78.3% below this industry median. Based on the distribution chart, Zhejiang Orient Gene Biotech Co ranks #454 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zhejiang Orient Gene Biotech Co has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Orient Gene Biotech Co's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #454 out of 811 companies for Receivables Turnover. This places Zhejiang Orient Gene Biotech Co in the lower half of its industry. The industry median Receivables Turnover is 5.58. Zhejiang Orient Gene Biotech Co's value of 1.21 is 78.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.58, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Orient Gene Biotech Co's current Receivables Turnover of 1.21 is 78.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Orient Gene Biotech Co's current Receivables Turnover is 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Orient Gene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co (SHSE:688298) is currently considered Possible Value Trap. The stock's GF Value™ is ¥31.28, compared to a current price of ¥18.94 — trading 39.5% below its estimated fair value. The current Receivables Turnover is 1.21 and 78.3% below the Medical Devices & Instruments industry median of 5.58. Zhejiang Orient Gene Biotech Co's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Zhejiang Orient Gene Biotech Co (SHSE:688298), the current Receivables Turnover is 1.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Orient Gene Biotech Co (SHSE:688298) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co stock appears to be undervalued.
The current stock price of ¥18.94 is trading 39.5% below its estimated GF Value™ of ¥31.28.
GuruFocus considers Zhejiang Orient Gene Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688298:
Receivables Turnover: 1.21
GF Value™: ¥31.28 vs. price of ¥18.94 (39.5% below fair value)
Industry Position: 78.3% below the Medical Devices & Instruments median (#454 of 811)
No single metric tells the full story. See the SHSE:688298 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Orient Gene Biotech Co Ltd is engaged in production, research, development and sale of vitro diagnostic products. The company's products include Genetic diagnosis, Colloidal gold rapid diagnostic tests, Dry chemical strips (urinalysis), Bio-liquid diagnostic kits, Clinical test instruments, POCT time-resolved Fluor immunoassay Test kit (TRFI), and Raw materials.
57GF Score
Get the complete analysis for SHSE:688298
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688298 has been successfully added to your 
